Wall Street analyst estimates for Bruker Corporation (BRKR): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Bruker Corporation stands as a prominent global developer, manufacturer, and distributor of cutting-edge scientific instruments, alongside comprehensive analytical and diagnostic solutions. Its operations are structured across three distinct segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 17 |
| Hold | 14 |
| Sell | 2 |
| Strong Sell | 0 |
| Total analysts | 33 |
| Avg rating (1-5) | 0.46 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-02 | $0.42 | ||
| 2026-08-04 | $0.49 | $0.38 | +27.3% |
| 2026-05-06 | $0.31 | $0.23 | +34.8% |
| 2026-02-12 | $0.59 | $0.65 | -9.2% |
| 2025-11-03 | $0.60 | $0.33 | +81.8% |
| 2025-08-04 | $0.32 | $0.33 | -3.0% |
| 2025-05-07 | $0.47 | $0.46 | +2.2% |
| 2025-02-13 | $0.76 | $0.75 | +1.3% |
Valuation Ratios
| Price / Book | 4.01 |
| EV / EBITDA | 46.23 |
| Dividend Yield | 0.32% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.61B | $1.77B | $1.90B | $2.07B | $1.99B | $2.42B | $2.53B | $2.96B | $3.37B | $3.44B |
| Cost of Revenue | $868.8M | $952.9M | $995.6M | $1.08B | $1.05B | $1.21B | $1.23B | $1.45B | $1.72B | $1.86B |
| Gross Profit | $742.5M | $813.0M | $900.0M | $995.3M | $939.8M | $1.21B | $1.31B | $1.51B | $1.65B | $1.58B |
| Research & Development | $149.0M | $162.7M | $173.4M | $187.7M | $198.0M | $220.8M | $235.9M | $294.8M | $376.5M | $395.2M |
| Selling, General & Admin | $390.5M | $415.9M | $444.7M | $504.8M | $477.8M | $562.3M | $607.4M | $729.4M | $893.8M | $946.5M |
| Operating Expenses | $539.5M | $578.6M | $618.1M | $694.4M | $691.5M | $796.3M | $873.0M | $1.08B | $1.40B | $1.34B |
| Operating Income | $177.2M | $214.7M | $262.4M | $300.9M | $248.3M | $413.3M | $432.7M | $436.9M | $253.1M | $236.0M |
| EBITDA | $262.1M | $299.5M | $340.1M | $372.0M | $320.6M | $497.1M | $518.7M | $675.5M | $438.6M | $302.6M |
| Interest Expense | $13.2M | $15.4M | $12.6M | $16.0M | $14.4M | $14.3M | $16.1M | $16.4M | $47.9M | $60.3M |
| Pre-tax Income | $177.6M | $197.8M | $244.7M | $280.4M | $225.8M | $393.6M | $414.9M | $546.2M | $205.2M | $21.0M |
| Income Tax | $23.1M | $117.5M | $63.7M | $82.4M | $64.4M | $113.0M | $116.4M | $117.7M | $91.4M | $29.3M |
| Net Income | $153.6M | $78.6M | $179.7M | $197.2M | $157.8M | $277.1M | $296.6M | $427.2M | $113.1M | -$8.6M |
| EPS | $0.95 | $0.50 | $1.15 | $1.27 | $1.03 | $1.83 | $2.00 | $2.92 | $0.76 | $-0.15 |
| EPS (Diluted) | $0.95 | $0.49 | $1.14 | $1.26 | $1.02 | $1.81 | $1.99 | $2.90 | $0.76 | $-0.15 |
| Shares Outstanding (Diluted) | $162.2M | $159.1M | $157.2M | $156.6M | $154.6M | $152.9M | $149.4M | $147.2M | $149.5M | $151.8M |
Price
| Price | $63.88 |
| Market Cap | $9.7B |
| Exchange | NASDAQ |
| Country | US |
Related companies: BTSG · CHE · CRSP · GKOS · IRTC · KRYS · MMSI
Explore sector: Healthcare · Medical - Devices
More sections of BRKR: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks